Shopping Cart 0
Cart Subtotal
USD 0

Thromboembolism - Pipeline Review, H1 2019

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Thromboembolism-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism-Pipeline Review, H1 2019, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape.

When a blood clot (thrombus) breaks and travels in the blood, this is called a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thromboembolism-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Thromboembolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thromboembolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 3, 1, 2, 7, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Thromboembolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Thromboembolism (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Thromboembolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Thromboembolism (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Thromboembolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Thromboembolism (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Thromboembolism (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Thromboembolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

Introduction

Thromboembolism-Overview

Thromboembolism-Therapeutics Development

Thromboembolism-Therapeutics Assessment

Thromboembolism-Companies Involved in Therapeutics Development

Thromboembolism-Drug Profiles

Thromboembolism-Dormant Projects

Thromboembolism-Discontinued Products

Thromboembolism-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Thromboembolism, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019


List Of Table

List of Tables

Number of Products under Development for Thromboembolism, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Thromboembolism-Pipeline by Accu-Break Pharmaceuticals Inc, H1 2019

Thromboembolism-Pipeline by Bayer AG, H1 2019

Thromboembolism-Pipeline by China Biologic Products Inc, H1 2019

Thromboembolism-Pipeline by Daiichi Sankyo Co Ltd, H1 2019

Thromboembolism-Pipeline by Dong-A Socio Holdings Co Ltd, H1 2019

Thromboembolism-Pipeline by F. Hoffmann-La Roche Ltd, H1 2019

Thromboembolism-Pipeline by GC Pharma, H1 2019

Thromboembolism-Pipeline by Ionis Pharmaceuticals Inc, H1 2019

Thromboembolism-Pipeline by Johnson & Johnson, H1 2019

Thromboembolism-Pipeline by Laboratorios Farmaceuticos Rovi SA, H1 2019

Thromboembolism-Pipeline by Portola Pharmaceuticals Inc, H1 2019

Thromboembolism-Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2019

Thromboembolism-Pipeline by Tetherex Pharmaceuticals Corp, H1 2019

Thromboembolism-Pipeline by Verseon Corp, H1 2019

Thromboembolism-Dormant Projects, H1 2019

Thromboembolism-Dormant Projects, H1 2019 (Contd..1), H1 2019

Thromboembolism-Discontinued Products, H1 2019

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Thromboembolism Therapeutic Products under Development, Key Players in Thromboembolism Therapeutics, Thromboembolism Pipeline Overview, Thromboembolism Pipeline, Thromboembolism Pipeline Assessment


Companies

Accu-Break Pharmaceuticals Inc

Bayer AG

China Biologic Products Inc

Daiichi Sankyo Co Ltd

Dong-A Socio Holdings Co Ltd

F. Hoffmann-La Roche Ltd

GC Pharma

Ionis Pharmaceuticals Inc

Johnson & Johnson

Laboratorios Farmaceuticos Rovi SA

Portola Pharmaceuticals Inc

Tasly Pharmaceutical Group Co Ltd

Tetherex Pharmaceuticals Corp

Verseon Corp

Thromboembolism-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism-Pipeline Review, H1 2019, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape.

When a blood clot (thrombus) breaks and travels in the blood, this is called a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thromboembolism-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Thromboembolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thromboembolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 3, 1, 2, 7, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Thromboembolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Thromboembolism (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Thromboembolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Thromboembolism (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Thromboembolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Thromboembolism (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Thromboembolism (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Thromboembolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents

Introduction

Thromboembolism-Overview

Thromboembolism-Therapeutics Development

Thromboembolism-Therapeutics Assessment

Thromboembolism-Companies Involved in Therapeutics Development

Thromboembolism-Drug Profiles

Thromboembolism-Dormant Projects

Thromboembolism-Discontinued Products

Thromboembolism-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Thromboembolism, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019


List Of Table

List of Tables

Number of Products under Development for Thromboembolism, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Thromboembolism-Pipeline by Accu-Break Pharmaceuticals Inc, H1 2019

Thromboembolism-Pipeline by Bayer AG, H1 2019

Thromboembolism-Pipeline by China Biologic Products Inc, H1 2019

Thromboembolism-Pipeline by Daiichi Sankyo Co Ltd, H1 2019

Thromboembolism-Pipeline by Dong-A Socio Holdings Co Ltd, H1 2019

Thromboembolism-Pipeline by F. Hoffmann-La Roche Ltd, H1 2019

Thromboembolism-Pipeline by GC Pharma, H1 2019

Thromboembolism-Pipeline by Ionis Pharmaceuticals Inc, H1 2019

Thromboembolism-Pipeline by Johnson & Johnson, H1 2019

Thromboembolism-Pipeline by Laboratorios Farmaceuticos Rovi SA, H1 2019

Thromboembolism-Pipeline by Portola Pharmaceuticals Inc, H1 2019

Thromboembolism-Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2019

Thromboembolism-Pipeline by Tetherex Pharmaceuticals Corp, H1 2019

Thromboembolism-Pipeline by Verseon Corp, H1 2019

Thromboembolism-Dormant Projects, H1 2019

Thromboembolism-Dormant Projects, H1 2019 (Contd..1), H1 2019

Thromboembolism-Discontinued Products, H1 2019

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Thromboembolism Therapeutic Products under Development, Key Players in Thromboembolism Therapeutics, Thromboembolism Pipeline Overview, Thromboembolism Pipeline, Thromboembolism Pipeline Assessment


Companies

Accu-Break Pharmaceuticals Inc

Bayer AG

China Biologic Products Inc

Daiichi Sankyo Co Ltd

Dong-A Socio Holdings Co Ltd

F. Hoffmann-La Roche Ltd

GC Pharma

Ionis Pharmaceuticals Inc

Johnson & Johnson

Laboratorios Farmaceuticos Rovi SA

Portola Pharmaceuticals Inc

Tasly Pharmaceutical Group Co Ltd

Tetherex Pharmaceuticals Corp

Verseon Corp